• No results found

Nytt om faget: Kardio-onkolgi

N/A
N/A
Protected

Academic year: 2022

Share "Nytt om faget: Kardio-onkolgi"

Copied!
26
0
0

Laster.... (Se fulltekst nå)

Fulltekst

(1)

Nytt om faget: Kardio-onkolgi

Geeta Gulati

Lege i spesialisering kardiologi OUS-Ullevål/

stipendiat Akershus universitetssykehus

20-10-2017

(2)

Agenda

Kardio-onkologi

Retningslinjer

(3)

Oppav til kardio-onkolgoien

Opphav til kardio-onkologien

(4)

163 235 279 412 533

1060

1580

2250 3010

5250 5800

0 1000 2000 3000 4000 5000

Google search

«Cardio- Oncology»

Numbers

Year

(5)

- Maximize benefits of modern cancer

therapy by minimizing its deleterious effects on the cardiovascular system

- Provide recognition and treatment of

cardiac complications in patients with or

who survive cancer

(6)
(7)

9 Pillars of Cardio- Oncology

1. Myocardial

dysfunction & heart failure

2. Coronary artery disease

3. Valvular disease 4. Arrhytmias

5. Hypertension

6. Thromboembolic

7. Peripheral vascular disase & stroke

8. Pulmonary hypertension

9. Pericardial

complications

August 2016

(8)

Normal

LVEF* > 50%

Lymfom behandlet

LVEF ~ 15%

*Left ventricular ejection fraction

(9)

Kjemoterapi

• Antrasykliner (epirubicin, daunorubicin, doksorubicin)

• Trastuzumab (Herceptin®)

(10)

Kreftcelle A A A

(11)

Top* 2β

A A

Mitochondria

DNA

Vejpongsa et al, J Am Coll Cardiol. 2014 (simplified and revised)

*Topoisomerase

**Reactive oxygen species

**

(12)

Felker GM et al. N Engl J Med 2000;342:1077-1084.

Adjusted Kaplan–Meier Estimates of Survival According to the Underlying Cause of Cardiomyopathy.

(13)

HER2

HER2*

Kreftcelle

*Human epidermal growth factor receptor 2

(14)

Kardiotoksisitet

Fall i LVEF* > 10% poeng til en verdi

< 50%

*Left ventricular ejection fraction

(15)

I am a security monitor

https://www.youtube.com/watch?v=x8FNVsbn wWE

(16)

Hvem

Høy-risiko for å utvikle hjertesvikt

Signifikant fall i LVEF*

Beta-blokker og ACE**-hemmer

*LVEF: left ventricular ejection fraction

**ACE: angiontensin converting enzyme

(17)

Modifisert kasuistikk

(18)

9 Pillars of Cardio- Oncology

1. Myocardial

dysfunction & heart failure

2. Coronary artery disease

3. Valvular disease 4. Arrhytmias

5. Hypertension

6. Thromboembolic

7. Peripheral vascular disase & stroke

8. Pulmonary hypertension

9. Pericardial

complications

August 2016

(19)

Cisplatin  testikkelkreft og lungekreft 5-fluorouracil  tarmkreft

Stråling

(20)

Brystkreft

(21)

Lymfom

(22)

Aortainsuffisiens,

parasternal langaksebilde

Aortainsuffisiens,

parasternal langaksebilde Normal aortaklaff

(23)

9 Pillars of Cardio- Oncology

1. Myocardial

dysfunction & heart failure

2. Coronary artery disease

3. Valvular disease 4. Arrhytmias

5. Hypertension

6. Thromboembolic

7. Peripheral vascular disase & stroke

8. Pulmonary hypertension

9. Pericardial

complications

August 2016

(24)

Normal 4-kammerbilde Pulmonal hypertensjon

(25)
(26)

Konklusjon

1. Kardio-onkologi er et voksende fagfelt

2. Kardio-onkologi består av 9 pillarer, med mest fokus på hjertedysfunksjon

3. Tidlig oppfølging er viktig

Referanser

RELATERTE DOKUMENTER

Kaplan – Meier survival analysis of complete success (defined as eyes with intraocular pressure ≤ 16 mmHg without need for anti-glaucoma medication after circumferential

Kaplan-Meier curves showing overall survival after high-dose therapy with autologous stem cell transplantation (HDT-ASCT) for relapsed/refractory Hodgkin lymphoma for the entire

Kaplan – Meier survival analyses of PD outcomes were performed in groups strati fi ed according to constipation severity, with date of diagnosis as time = 0, and censoring at the

Kaplan Meier curves displaying biochemical failure free survival (BFFS), clinical failure free survival (CFFS) and prostate cancer death free survival (PCDFS) in relation to high

Kaplan-Meier survival estimates were used to evaluate the prognostic value of CMKLR1 (A, B) and GPR1 (D, E) expression in two patient data sets (A and D: Versteeg n=88; B and E:

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/foods10061268/s1, Figure S1: Weighted Kaplan–Meier estimates of the

* the log-rank P value (Kaplan Meier statistics; comparing 5 year survival between Carboplatin and Cisplatin treated patients)

Figure 2 Kaplan-Meier survival plots presenting recurrence-free survival (upper row) and overall survival (lower row) based on nuclear expression of B7-H3 (B7-H3N) in tumour